Novel models for assessing blood–brain barrier drug permeation

Bibliography

• Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007;12(1-2):54-61
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Berezowski V, Lundquist S, Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6(8):650-61
   PubMed Web of Science ®Google Scholar
• Mahringer A, Ott M, Reimold I, The ABC of the blood-brain barrier - regulation of drug efflux pumps. Curr Pharm Des 2011;17(26):2762-70
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr Opin Drug Discov Dev 2002;5(1):33-43
   PubMedGoogle Scholar
• van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003;2(3):192-204
   PubMed Web of Science ®Google Scholar
• Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7(2):165-82
   PubMed Web of Science ®Google Scholar
• Rice A, Liu Y, Michaelis ML, Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J Med Chem 2005;48(3):832-8
   PubMedGoogle Scholar
• Deftereos SN, Andronis C, Friedla EJ, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 2011;3(3):323-34
   PubMedGoogle Scholar
• Pan SY, Pan S, Yu ZL, New perspectives on innovative drug discovery: an overview. J Pharm Pharm Sci 2010;13(3):450-71
   Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-85
   PubMed Web of Science ®Google Scholar
• Morgan S, Grootendorst P, Lexchin J, The cost of drug development: a systematic review. Health Policy 2011;100(1):4-17
   PubMed Web of Science ®Google Scholar
• Dove A. Drug screening–beyond the bottleneck. Nat Biotechnol 1999;17(9):859-63
   PubMedGoogle Scholar
• Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today 2003;8(20):927-33
   PubMed Web of Science ®Google Scholar
• Williams CH, Hong CC. Multi-step usage of in vivo models during rational drug design and discovery. Int J Mol Sci 2011;12(4):2262-74
   PubMedGoogle Scholar
• Liebner S, Czupalla CJ, Wolburg H. Current concepts of blood-brain barrier development. Int J Dev Biol 2011;55(4-5):467-76
   PubMed Web of Science ®Google Scholar
• Mittapalli RK, Manda VK, Adkins CE, Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. Ther Deliv 2011;1(6):775-84
   Google Scholar
• Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 2011;13:e19
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Structure and function of the blood-brain barrier. Neurobiology Dis 2010;37(1):13-25
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 2005;25(1):5-23
   PubMed Web of Science ®Google Scholar
• Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40(3):648-77
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point of view. Anat Rec B New Anat 2006;289(1):3-8
   PubMedGoogle Scholar
• Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47-62
   PubMed Web of Science ®Google Scholar
• Thrimawithana TR, Young S, Bunt CR, Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16(5-6):270-7
   PubMed Web of Science ®Google Scholar
• Runkle EA, Antonetti DA. The blood-retinal barrier: structure and functional significance. Methods Mol Biol 2011;686:133-48
   PubMedGoogle Scholar
• Abbott NJ, Dolman DE, Patabendige AK. Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 2008;9(9):901-10
   PubMedGoogle Scholar
• Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 2011;89(6):798-805
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target 2010;18(3):157-67
   PubMed Web of Science ®Google Scholar
• Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv 2010;10(5):293-304
   PubMedGoogle Scholar
• Ni Z, Bikadi Z, Rosenberg MF, Mao Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 2010;11(7):603-17
   PubMed Web of Science ®Google Scholar
• Agarwal S, Hartz AM, Elmquist WF, Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des 2011;17(26):2793-802
   PubMed Web of Science ®Google Scholar
• Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR. Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity. J Neurochem 2010;115(2):515-25
   PubMed Web of Science ®Google Scholar
• Manda VK, Mittapalli RK, Bohn KA, Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 2010;115(6):1495-507
   PubMedGoogle Scholar
• Geldenhuys W, Mbimba T, Bui T, Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 2011;19(9):837-45
   PubMed Web of Science ®Google Scholar
• Carroll RT, Bhatia D, Geldenhuys W, Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010;18(9):665-74
   PubMed Web of Science ®Google Scholar
• Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp 2011;71(1):113-28
   PubMed Web of Science ®Google Scholar
• Vandenhaute E, Sevin E, Hallier-Vanuxeem D, Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery. Drug Discov Today 2011; in press
   PubMedGoogle Scholar
• DeSalvo MK, Mayer N, Mayer F, Bainton RJ. Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila. Glia 2011;59(9):1322-40
   PubMedGoogle Scholar
• Nakagawa S, Deli MA, Kawaguchi H, A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009;54(3-4):253-63
   PubMed Web of Science ®Google Scholar
• Edwards TN, Meinertzhagen IA. The functional organisation of glia in the adult brain of Drosophila and other insects. Prog Neurobiol 2010;90(4):471-97
   PubMed Web of Science ®Google Scholar
• Mayer F, Mayer N, Chinn L, Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci 2009;29(11):3538-50
   PubMed Web of Science ®Google Scholar
• Nielsen PA, Andersson O, Hansen SH, Models for predicting blood-brain barrier permeation. Drug Discov Today 2011;16(11-12):472-5
   PubMed Web of Science ®Google Scholar
• Segalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem Biol 2007;2(4):231-6
   PubMed Web of Science ®Google Scholar
• Swales LS, Lane NJ. Embryonic development of glial cells and their junctions in the locust central nervous system. J Neurosci 1985;5(1):117-27
   PubMedGoogle Scholar
• Schofield PK, Threherne JE. Localization of the blood-brain barrier of an insect: electrical model and analysis. J Exp Biol 1984;109:319-31
   Google Scholar
• Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 2007;30:235-58
   PubMed Web of Science ®Google Scholar
• Van Itallie CM, Anderson JM. The molecular physiology of tight junction pores. Physiology (Bethesda) 2004;19:331-8
   PubMed Web of Science ®Google Scholar
• Giacomotto J, Segalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol 2010;160(2):204-16
   PubMed Web of Science ®Google Scholar
• Stork T, Engelen D, Krudewig A, Organization and function of the blood-brain barrier in Drosophila. J Neurosci 2008;28(3):587-97
   PubMed Web of Science ®Google Scholar
• Pandey UB, Nichols CD. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol Rev 2011;63(2):411-36
   PubMed Web of Science ®Google Scholar
• Dehay B, Bezard E. New animal models of Parkinson's disease. Mov Disord 2011;26(7):1198-205
   PubMedGoogle Scholar
• Liu Z, Hamamichi S, Lee BD, Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 2011;20(20):3933-42
   PubMedGoogle Scholar
• Bainton RJ, Tsai LT, Schwabe T, moody encodes two GPCRs that regulate cocaine behaviors and blood-brain barrier permeability in Drosophila. Cell 2005;123(1):145-56
   PubMedGoogle Scholar
• Pinsonneault RL, Mayer N, Mayer F, Novel models for studying the blood-brain and blood-eye barriers in Drosophila. Methods Mol Biol 2011;686:357-69
   PubMedGoogle Scholar
• Tan JL, Zon LI. Chemical screening in zebrafish for novel biological and therapeutic discovery. Methods Cell Biol 2011;105:493-516
   PubMedGoogle Scholar
• Saydmohammed M, Vollmer LL, Onuoha EO, A high-content screening assay in transgenic zebrafish identifies two novel activators of fgf signaling. Birth Defects Res C Embryo Today 2011;93(3):281-7
   PubMedGoogle Scholar
• Rihel J, Schier AF. Behavioral screening for neuroactive drugs in zebrafish. Dev Neurobiol 2012;72:373-85
   PubMed Web of Science ®Google Scholar
• Kawahara G, Karpf JA, Myers JA, Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2011;108(13):5331-6
   PubMed Web of Science ®Google Scholar
• Clifton JD, Lucumi E, Myers MC, Identification of novel inhibitors of dietary lipid absorption using zebrafish. PloS One 2010;5(8):e12386
   Google Scholar
• Lessman CA. The developing zebrafish (Danio rerio): a vertebrate model for high-throughput screening of chemical libraries. Birth Defects Res C Embryo Today 2011;93(3):268-80
   PubMed Web of Science ®Google Scholar
• Farrell TC, Cario CL, Milanese C, Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiol Dis 2011;44(1):9-18
   PubMed Web of Science ®Google Scholar
• Jeong JY, Kwon HB, Ahn JC, Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res Bull 2008;75(5):619-28
   PubMed Web of Science ®Google Scholar
• Xie J, Farage E, Sugimoto M, Anand-Apte B. A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development. BMC Dev Biol 2010;10:76
   Google Scholar
• Lockman PR, Mittapalli RK, Taskar KS, Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16(23):5664-78
   PubMed Web of Science ®Google Scholar
• Carlson SD, Juang JL, Hilgers SL, Garment MB. Blood barriers of the insect. Annu Review Entomol 2000;45:151-74
   PubMed Web of Science ®Google Scholar